When the VEGF-A-targeting monoclonal antibody bevacizumab (Avastin®) entered clinical
practice more than 15 years ago, it was one of the first targeted therapies and the first …

Introduction Breast cancer remains a significant scientific, clinical and societal challenge.
This gap analysis has reviewed and critically assessed enduring issues and new challenges …

Varied cellular expression and localisation of nitric oxide synthase (NOS) isoforms has
been shown in human cancers, including tumours of the breast, ovary, stomach, cervix and …

Background Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate incorporating
the human epidermal growth factor receptor 2 (HER2)–targeted antitumor properties of …

Purpose: Docetaxel and capecitabine, a tumor-acti-vated oral fluoropyrimidine, show high
single-agent efficacy in metastatic breast cancer (MBC) and synergy in preclinical studies. …

Purpose The efficacy and safety of combining bevacizumab (7.5 and 15 mg/kg) with
docetaxel as first-line therapy for human epidermal growth factor receptor 2 (HER2) –negative, …

Background CLEOPATRA was a phase 3 study comparing the efficacy and safety of pertuzumab,
trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel in patients with …

Purpose Pertuzumab, a human epidermal growth factor receptor 2 (HER2)–targeted monoclonal
antibody, potently inhibits HER2 dimerization and HER-mediated signaling pathways. …

This article assesses the impact of Quantitative Easing and other unconventional monetary
policies followed by central banks in the wake of the financial crisis that began in 2007. We …

This article reports estimates of the long‐run costs and benefits of having banks fund more
of their assets with loss‐absorbing capital, or equity. We model how shifts in funding affect …